Xiaolei Yuan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaolei Yuan has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Feng Zhang
Department of Ultrasound, The 2nd Affiliated Hospital of Harbin Medical University, NO.246, Xuefu Road, Nangang District, Harbin, 150081, Heilongjiang, People's Republic of China
1 shared publication - Jia Tianshuang
Department of Ultrasound, The 2nd Affiliated Hospital of Harbin Medical University, NO. 246, Xuefu Road, Nangang District, Harbin, 150081, Heilongjiang, China
1 shared publication - Kexin Chen
Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, China
1 shared publication - Kexin Han
Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, China
1 shared publication - Litao Sun
Cancer Center, Department of Ultrasound Medicine, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, People’s Republic of China
1 shared publication - Lu Rui
Department of Ultrasound, The 1st Affiliated Hospital of Hainan Medical University, NO. 31, Longhua Road, Longhua District, Haikou, 570102, Hainan, China
1 shared publication
Latest Publications
- 28 April 2026
- Published by Springer Nature in Inflammation Research
- Vol. 75 (1) , 102
Integrated multi-omics profiling reveals the potential role of maternal systemic immune dysregulation driven by monocyte/macrophage in preeclampsia
- 28 April 2026
- Published by Springer Nature in Inflammation Research
- Vol. 75 (1) , 102
Integrated multi-omics profiling reveals the potential role of maternal systemic immune dysregulation driven by monocyte/macrophage in preeclampsia
- Open Access
- 7 January 2021
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 14 (1) , 1-10
Long non-coding RNA FAM83H-AS1 acts as a potential oncogenic driver in human ovarian cancer
Objective: Ovarian cancer (OC) is one of the most aggressive women cancers with increasing incidence and mortality rates worldwide. Long non-coding RNAs (lncRNAs) could as major players in OC process. Although FAM83H antisense RNA1 (FAM83H-AS1) is demonstrated play an important roles in a many cancers, the detailed function and mechanism has not been reported in OC. Results: We integrated multiple kinds of bioinformatics approaches and experiments validated method to evaluate functions of FAM83H-AS1 in OC. Some differential expressed lncRNAs were identified between OC and normal control tissues. FAM83H-AS1 was one of most differentially expressed lncRNAs and up-regulated in multiple cancer types. Specially, expression of FAM83H-AS1 was higher in OC and showed difference in diverse stages. High FAM83H-AS1 expression is associated with worse pan-cancer and OC outcomes. FAM83H-AS1-centric network including lncRNA-miRNA, lncRNA-protein and lncRNA-mRNA ceRNA network were constructed to infer the function and mechanism of FAM83H-AS1. There were two methylation sites including cg01399317 and cg20519035 located at FAM83H-AS1. The methylation level of cg01399317 was correlated with gene expression of FAM83H-AS1. The expression level of FAM83H-AS1 was correlated with infiltration level of immune cell including macrophage, neutrphil and dendritic cell in OC patients. Lastly, qRT-PCR showed that the expression of FAM83H-AS1 was higher in OC tissues than normal control tissues. Conclusion: Collectively, these results indicated that FAM83H-AS1 may act as an oncogenic driver and it may be a potential therapy target in OC.
- 7 January 2021
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 14 (1) , 1-10
Open AccessLong non-coding RNA FAM83H-AS1 acts as a potential oncogenic driver in human ovarian cancer
Objective: Ovarian cancer (OC) is one of the most aggressive women cancers with increasing incidence and mortality rates worldwide. Long non-coding RNAs (lncRNAs) could as major players in OC process. Although FAM83H antisense RNA1 (FAM83H-AS1) is demonstrated play an important roles in a many cancers, the detailed function and mechanism has not been reported in OC. Results: We integrated multiple kinds of bioinformatics approaches and experiments validated method to evaluate functions of FAM83H-AS1 in OC. Some differential expressed lncRNAs were identified between OC and normal control tissues. FAM83H-AS1 was one of most differentially expressed lncRNAs and up-regulated in multiple cancer types. Specially, expression of FAM83H-AS1 was higher in OC and showed difference in diverse stages. High FAM83H-AS1 expression is associated with worse pan-cancer and OC outcomes. FAM83H-AS1-centric network including lncRNA-miRNA, lncRNA-protein and lncRNA-mRNA ceRNA network were constructed to infer the function and mechanism of FAM83H-AS1. There were two methylation sites including cg01399317 and cg20519035 located at FAM83H-AS1. The methylation level of cg01399317 was correlated with gene expression of FAM83H-AS1. The expression level of FAM83H-AS1 was correlated with infiltration level of immune cell including macrophage, neutrphil and dendritic cell in OC patients. Lastly, qRT-PCR showed that the expression of FAM83H-AS1 was higher in OC tissues than normal control tissues. Conclusion: Collectively, these results indicated that FAM83H-AS1 may act as an oncogenic driver and it may be a potential therapy target in OC.